Europabio

RARE DISEASES FORUM 2024
2024-04-16 08:30 - 12:00 (Europe/Brussels)
Against the backdrop of the Belgian EU Council Presidency, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations, industry and policy to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda.

About ‘The Rare Diseases Forum 2024: Securing Europe’s Competitiveness in R&D for people living with rare diseases’ features keynotes and panel discussions with a focus on the EU’s role in enhancing competitiveness in life sciences, fostering investment in the rare diseases sector, and examining the benefits of a competitive agenda for those with rare diseases.

The event is convened by Global Counsel on behalf of the forum partners, EURORDIS, RaDiOrg, EFPIA, Eucope, EuropaBio, Pharma.be, UCB, Novo Nordisk, Sanofi & Takeda.

Industrial biotech: Is Europe ready to harness its potential?
2024-03-19 14:30 - 16:45
A Science | Business closed-door roundtable, organised in partnership with EuropaBio – followed by networking reception

Only By Invitation

Background Information
In recent years industrial biotechnology – also known as “white” biotech – has emerged as a high-value driver of industrial modernisation and the green transition. Through the innovative use of microorganisms and enzymes, it has transformative potential for manufacturing, waste use and the creation of sustainable products in sectors as varied as energy, textiles, plastics, paper, agriculture and water. While some core processes, such as fermentation technology, have been commercially deployed for around 50 years, the speed of scientific progress and solution development are accelerating exponentially. As such, it appears that the sector as a whole is truly poised to make the leap from “proof of concept” to mainstream application at the European level.
These take on greater importance when one considers other strategic priorities for the EU. First, it is clear that for Europe to achieve e.g. its 2030 benchmark for net-zero technology manufacturing in the Green Deal Industrial Plan (GDIP), it will need to leverage its full innovation capacity across sectors. Second, as global demand grows for sustainable solutions to climate, energy, biodiversity and food system crises, Europe is ideally positioned to take market leadership in various domains, given its research excellence and strong industrial base. And third, the EU’s proposed Strategic Technologies for Europe Platform (STEP) has already identified biotechnologies among its key value chains to ensure future resilience, autonomy and competitiveness, while biotechnology has also been recognised as a critical technology for Europe.
Yet a degree of skepticism remains – both in public and policy circles – about the risk/reward ratio of biotechnologies and their wider value to society. One useful counterpoint is to consider the evolution of health-related biotechnology (often called “red” biotech). Having overcome similar resistance and concerns, “red” biotech is now deployed at scale throughout the life science and pharmaceutical sectors, and is acknowledged today as a key component in European health innovation. So how can the lessons learned on that journey be absorbed and applied to other sectors?
As the EU prepares for its transition to a new Parliament and Commission, it is therefore an ideal moment to open a multistakeholder dialogue on how policy and regulatory innovations could increase the European added value of “white” biotech and biomanufacturing in the years to come. This also builds on Ursula von der Leyen’s announcement of a new biotech and biomanufacturing initiative in last September’s state-of-the-union address. Among some of the key issues for consideration:
Where can industrial biotech and biomanufacturing contribute most effectively to the GDIP and STEP, and what are the longer-term implications for boosting the global competitiveness of European companies?
What should underpin a future EU roadmap for advancing “white” biotech and biomanufacturing across sectors, in line with other long-term strategies and objectives?
Which other steps are needed at EU and national level to build future capacity, such as infrastructure and skills?
In which ways can public and private finance best support pioneering “white” biotech firms – large and small – in scaling up and maturing their solutions to market-readiness and mass production levels, as has happened in the health sector?
Beyond the CBE Joint Undertaking, to what extent could Horizon Europe, FP10 and other key instruments – such as the new biotech & biomanufacturing initiative – strengthen Europe’s industrial biotech R&D ecosystem in the next policy cycle?
On March 19, Science|Business, in cooperation with EuropaBio, will convene a select group of senior figures and experts from across the industrial biotech spectrum to address these issues in a closed-door, invitation-only roundtable. Drawing in part on latest research and real-world applications, the meeting will identify recommendations to harness the full potential of “white” biotech and biomanufacturing, and to align its further development with the realisation of key EU policy goals.

For more information, please contact: denitsa.nikolova@sciencebusiness.ne

Click here for more information

Biomanufacturing Policy Summit 2024 - Policy pathways for biomanufacturing in Europe
2024-03-13 13:00 - 20:00
The Biomanufacturing Policy Summit will host its 2nd edition in March 2024. The invite-only half-day summit hosted by EuropaBio brings together stakeholders including industry representatives and policymakers, to discuss Europe’s ambitions for biomanufacturing and the tangible legislative, regulatory and strategic pathways.

2023 was a year of visibility and recognition for biomanufacturing in Europe. It saw the creation of the Strategic Technologies for Europe Platform (STEP) and the announcement of the EU Biotech and Biomanufacturing Initiative, plus the identification of biotechnology as a critical technology for Europe’s security. 2024 is expected to be a year in which initiatives gain policy momentum, within a new Parliament and Commission and begin to deliver practical and impactful instruments to European industries.

13:00 – Lunch14:00 – Welcome & Introduction14:10 – Keynote Speakers15:30 – Defragmenting and Accelerating Europe’s Biotech & Biomanufacturing – The Role of Policy “How does policy impact decisions for biomanufacturing companies in Europe across sectors?”16:15 – Coffee Break16:30 – Out of the Box – A Global View on Biomanufacturing Policies “What can Europe learn and lead from policy across global regions?”17:15 – How does Policy deliver for Biomanufacturing – Looking Ahead “The policy future for Europe, with recommendations for the incoming Commission and Parliament.”18:00 – Networking Reception

Participants will discuss how policy enables Europe to seize the opportunity for biomanufacturing within innovative, sustainable and critical products within global supply chains. The Summit will address policy pathways for how biotech and biomanufacturing can deliver results in competitiveness, Green Transition and resilience across sectors.

For all enquiries, please contact our Biomanufacturing Platform Coordinator, Francisco Castro Alves: f.alves@europabio.org

EuropaBio Webinar – How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies?
2024-03-07 13:00 - 14:30
Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies.

Following the publication on 24 January 2024 of a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem, EuropaBio is delighted to invite you to attend its exclusive webinar to discuss the consequences of this landmark legislation for the future of innovation in healthcare in Europe, EU patients and economies within a global race towards health security and competitiveness.

The event will start with a presentation of the study by Charles Rivers Associates and will be followed by a panel discussion featuring leading voices of the European biotechnology ecosystem to discuss the impact of the proposed legislation and its consequences on the development of breakthrough medicines for EU patients.

The webinar will take place on Thursday 7 March at 13.00 CET. If you wish to attend, please register below.

Agenda:

Welcome & Introduction: 13:00 – 13:05, Dr Claire Skentelbery, Director General EuropaBio

Report Presentation and Q&A: 13:05 – 13:30, Antun Sablek & Tim Wilsdon, Charles River Associates

Panel Discussion and Q&A: 13:30 – 14:25, Panelists: John James Ricketts, Noel Minnis, Thomas Bols, Tineke Van hooland, Wojciech Nowak and Yordan Aleksandrov. Moderated by Dr Claire Skentelbery.

Concluding Remarks: 14:25 – 14:30 Dr Claire Skentelbery, Director General EuropaBio

Speakers: Moderated by Dr Claire Skentelbery, EuropaBio

Antun Sablek, Charles River Associates

John James Ricketts, Eli Lilly

Noel Minnis, Takeda

Thomas Bols, PTC Therapeutics

Tim Wilsdon, Charles River Associates

Tineke Van hooland, Bio.be

Wojciech Nowak, Novartis

Yordan Aleksandrov, Pfizer

Register here

International Congress on Rare Diseases and Orphan Drugs 2024
2024-02-29 09:00 - 2024-03-01 17:00
Navigating the Uncharted: Advancements, Collaborations, and Hope in Rare Diseases

Supported by EuropaBio

About the event:

Embrace the extraordinary journey into the world of rare diseases at our groundbreaking International Congress, where innovation, collaboration, and hope converge!

The International Congress on Rare Diseases and Orphan Drugs is organized by Rare Diseases Greece (RDG), member of EURORDIS-Rare Diseases Europe and Boussias Events.

Following the success of the previous years and having advanced the policy agenda on both a national and international level, the Organizing Committee – consisting of Rare Diseases Greece (RDG), the 30-member umbrella organization that represents the country’s rare disease community, brings together all the key initiatives and stakeholders currently shaping the rare disease landscape with the aim to set a course for the future of rare diseases.

Attendance details:

Thursday, 29.02.2024 (Hybrid | Technopolis City of Athens Gasholder 1 – Auditorium “Miltiadis Evert”) & Friday, 01.03.2024 (Digital)

Register here

Find out more here

Made in Belgium for Europe, National Associations' Council Presidency Summit
2024-02-21 10:00 - 12:00
Whether it’s microorganisms revolutionising manufacturing or advanced therapies for rare disease patients, biotechnology is leading the way, and Belgium is on it.

If you are a researcher, entrepreneur, policy wonk, or simply curious about the future of biotechnology, join us in our free online conversation.

This conversation will be public and held online on February 21, 2024, from 10:00 to 12:00. If you wish to attend our session, please register. If you have any questions, insights or suggestions, do not hesitate to contact José Peres at j.peres@europabio.org.

Register here

Download the Agenda

Europe Rare Disease Summit 2024
2024-02-14 08:00 - 17:00
How to improve and learn about Government Plans, Access & Financing, Clinical Research and Innovation, Artificial Intelligence and Data, and Social & Patient.

Join our very own Healthcare Policy Senior Manager, Adrien Samson in Madrid where he will be speaking in the panel “Innovation, Funding and Access to Orphan Drugs: Challenges and Opportunities” between 12:15 and 13:00.

We are thrilled to announce the eagerly awaited second edition of the Europe Rare Disease Summit, set to take place in February. Joining forces from all corners of Europe, this prestigious event brings together leading researchers, healthcare professionals, patient advocates, policymakers, industry experts, and rare disease patients and families.

The summit emphasizes the power of collaboration and solidarity in facing rare diseases. Together, we can accelerate research, enhance patient care, and improve outcomes, offering a brighter future for those affected by rare diseases.

Key Objectives:

Empowering Patients: Putting patients at the heart of our efforts, we strive to enhance their access to quality care and support, while advocating for their rights and unique challenges.

Advancing Research: Renowned scientists will present groundbreaking discoveries, fostering cross-disciplinary collaboration to propel rare disease research forward.

Building Collaborative Networks: A platform for stakeholders to connect, exchange ideas, and form strategic partnerships, bridging gaps in research, treatment, and support.

Influencing Policy: By engaging policymakers, we seek to drive positive changes and better support the rare disease community.

Engaging Program Highlights: Expect a dynamic lineup of keynote speeches, interactive workshops, panel discussions and networking opportunities. Share experiences, learn from experts, and inspire change.

Location and Dates: Prepare to be inspired in the vibrant setting of Madrid on February 14th.

Who will Attend:

Rare Disease AdvocatesResearchers and ScientistsHealthcare ProfessionalsIndustry LeadersPolicymakers and Government RepresentativesPharmaceutical and Biotech CompaniesInvestors and Venture CapitalistsAcademics and Students

EU pharmaceutical legislation - Europe’s biotech innovation in the balance?
2024-01-24 12:00 - 15:00
Event agenda

12:00: Registration opens

12:30: Panel starts

13:45: Panel close and networking lunch

15:00: Close

Confirmed Speakers

Tomislav Sokol MEPMember SANT Committee, European Parliament

Hilde StevensCo-director, Institute for Interdisciplinary Innovation in Healthcare (I3H), ULB

Kristin ThompsonChief Operating Officer, eureKARE

Vivian TsevelekiChief Operating Officer, theraCell

More to be announced soon

Introduction

In April 2023, the European Commission adopted a proposal for a new Directive and a new Regulation, aimed at revising and replacing the existing General Pharmaceutical Legislation (GPL). The proposal focuses on modernising the pharmaceutical sector with a patient-centred approach, while also fully supporting an innovative and competitive industry.

Through the proposal, the EU aims to offer an attractive and innovation-friendly environment for research, development, and production of medicines in Europe. The EU plans to create this environment by promoting world-class innovation, governed by stable and consistent rules that keep pace with innovation and which increase competitiveness while reducing red tape and costs.

One of the sectors impacted by the proposal is that of biotechnology, which has been instrumental in the discovery and development of therapies, diagnostics, vaccines and, most importantly, advanced medicines. These ‘next generation medicines’ are delivered through a complex and interdependent biotechnology ecosystem, where companies of all sizes contribute to establishing a pathway to patients.

Join this Euractiv Hybrid Conference to discuss Europe’s biotech innovation in light of the EU’s reform of the General Pharmaceutical Legislation.

Questions to be discussed include:

How can Europe’s biotechnology industry maintain its competitiveness in the global medical market?

How can we establish a framework that fosters the growth of small biotech innovators?

What are the reactions of investors to the challenges faced by small biotech companies, and how do these reactions influence the trajectory of innovation in the biotech industry?

What strategies can be employed to establish a successful innovation pathway for biotech companies, while considering and aligning with the objectives of the reformed GPL?

IHI Call Days - Calls 6 & 7
2024-01-10 08:00 - 2024-01-25 17:00
The IHI Call Days are your one-stop-shop to get detailed information on our calls for proposals and network with potential partners for your consortium.

IHI call 7 (single-stage) – info sessions

10-12 January 2024

Call 7, topic 1: Improving clinical management of heart disease from early detection to treatmentWednesday 10 January | 10:30-11:30

Call 7, topic 2: User-centric technologies and optimised hospital workflows for a sustainable healthcare workforceWednesday 10 January | 14:30-15:30

IHI rules and procedures for single-stage callsThursday 11 January | 10:30-11:30

Call 7, topic 3: Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment responseThursday 11 January | 14:30-15:30

Managing the financial aspects of proposals for single-stage callsFriday 12 January | 10:30-11:30

IHI call 6 (two-stage) – info sessions

15-16 January 2024

IHI rules and procedures for two-stage callsMonday 15 January | 14:30-15:30

Call 6, topic 2: Development of practical guidance and recommendations for using real world data/real world evidence in healthcare decision-makingTuesday 16 January | 10:30-11:30

Call 6, topic 1: Support healthcare system resilience through a focus on persistency in the treatment of chronic diseasesTuesday 16 January | 14:30-15:30

IHI call 7 (single-stage) – pitching sessions

23-25 January 2024

Call 7, topic 1: Improving clinical management of heart disease from early detection to treatmentTuesday 23 January | 14:30-16:00

Call 7, topic 2: User-centric technologies and optimised hospital workflows for a sustainable healthcare workforceWednesday 24 January | 14:30-16:00

Call 7, topic 3: Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment responseThursday 25 January | 14:30-16:00

EFIB 2023 Rotterdam Statement wider launch
2023-12-01 08:30 - 09:45
Industrial biotechnology for a sustainable and resilient global Europe

As the EU looks ahead to the European elections in 2024, with a new EU Commission mandate and Work Programme, EuropaBio reviews European strategies and ambitions where biotechnology plays a key role. Ursula von der Leyen’s State of the European Union address of 13 September announced an ‘EU Biotech and Biomanufacturing Initiative’. The announced EU initiative is the latest indication of a greater point of recognition and acceleration for biotechnology.

Building on this momentum, the EFIB Rotterdam Statement of 2023 provides a priority pathway for biotechnology to support Europe’s global leadership, resilience and competitiveness.

We invite you to join us for a discussion on the role and potential of biotechnology and Europe’s global position in the context of the 2024 EU election.

Invitation Only Event

EuropaBio Patient BioForum 2023 Roundtable on Advancing Solutions for Unmet Medical Needs
2023-11-30 14:30 - 16:00
Hybrid Event | Invitation Only

EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific, regulatory, and policy issues between patient organisations and the biopharmaceutical industry.

In recent years, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. To address unmet medical needs (UMN), the Commission proposed as part of the revision of the EU General Pharmaceutical Legislation (GPL) to introduce a definition of UMN and a definition of high UMN. Under the Commission’s proposals, all orphan products would qualify as addressing UMN but only a subset of products would meet the HUMN criteria. The Commission’s proposals on UMN and especially HUMN received mixed reactions from patient organisations and negative reactions from the industry.

On 1 December 2022, EuropaBio organised a Patient BioForum which brought together industry and patient organisations to discuss the topic of UMN in view of reaching a common understanding on UMN. Those discussions revealed shared interests and concerns with the possible approach to UMN in the EU Pharmaceutical Legislation. The discussions were followed by a report which outlined recommendations to policymakers to enable Europe to address the challenge of UMN.

With the proposals now presented and being negotiated by the European Parliament and the Council, the 2023 Patient BioForum is an opportunity to build on the 2022 Patient BioForum to foster exchanges between patient groups and industry on UMNs, including expectations from the legislation and beyond. The 2023 Patient BioForum will also be an opportunity to issue multi-stakeholder recommendations to policymakers to ensure the GPL is fit for purpose to address patients need and support innovation.

Programme

The 2023 Patient BioForum will be held in a roundtable format under Chatham House Rule. A wide range of stakeholders representing patients, regulators, policy-makers, and industry will be invited to take part in the roundtable. All participants will be invited to take an active part in the discussion to bring their unique perspective. The roundtable will be followed by a report to summarise the discussions.

1. Introductions

2. Legislating Unmet Medical Needs: Perspectives from the European Commission and the European Parliament

3. Roundtable topic 1: How Can the EU Pharmaceutical Legislation Help Stimulate Patient-Centric Innovation?

4. Roundtable topic 2: How can Europe Incentivise R&D for UMN and Underserved Areas?

5. Conclusions

If you would like to attend, please contact Adrian Lincoln, a.lincoln@europabio.org

BIO Europe 2023
2023-11-06 15:30 - 16:30
The European Pharmaceutical Legislation – Will it keep the light on for biotech in Europe?

Join our Director General, Dr. Claire Skentelbery on the 6th of November in Munich for her panel discussing what the legislation brings, its potential impact on businesses and what needs to be done to change the legislation in its journey to a final version, that it works for both, the biotech ecosystem, maintaining innovation pipelines, and patients.

World Orphan Drug Congress
2023-11-01 08:00 - 2023-11-02 17:00
The World Orphan Drug Congress is the largest and most established orphan drugs & rare diseases meeting of its kind across the globe.

Join our Director General, Dr. Claire Skentelbery on the 1st of November for her Keynote Panel: How to navigate the new legislation to enable orphan drug developers to stay innovative and profitable in Europe.

As well as on the 2nd on November for her Panel: How to enable SME’s to obtain greater market access.

EFIB 2023 - Industrial biotechnology for a sustainable and resilient global Europe
2023-10-24 08:00 - 2023-10-25 17:00
EuropaBio is pleased to announce that this year’s edition of EFIB, Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy under the title ‘Industrial biotechnology for a sustainable and resilient global Europe’, will take place 24-25 October 2023 in Rotterdam, The Netherlands. EuropaBio is partnering with local hosts HollandBio and ChemistryNL to bring EFIB 2023 to Rotterdam.

Now in its 16th year, EFIB will be dedicated to exploring how industrial biotechnology and the bioeconomy supports European competitiveness. EFIB brings together professionals from across the value chain to discuss advancements from industrial biotechnology and its contribution towards positioning Europe as a global leader in addressing societal and sustainability challenges. Participants include industry of all sizes, as well as the community that enables industry to deliver, including researchers, policy makers, regulators, and global organisations.

Our two-day programme includes inspiring plenaries, a start-up pitching hour and will explore our four thematic areas – Food, Feed & Nutrition; Sustainable Biomaterials; Bioprocesses & Technologies; and Sustainable Finance – as well as new frontiers like biomanufacturing. The programme is complemented by the exhibition: including start-ups and SMEs in our SME Village, the academic poster presentation in our Innovation Campus, and exhibitors from industry and national associations. Interested in exhibiting? Check out our sponsorship page.

Attending EFIB 2023 will allow you to learn about the latest market trends and research findings in industrial biotechnology and network with key stakeholders.

Register Here

For more information visit our website and subscribe to our newsletter.

TOPRA Symposium 2023: advancing global healthcare together
2023-10-23 12:40 - 14:10
Session: Update on EU new regulatory legislation and a view from different angles

Join our very own Valentin Plouchard who will be speaking at the TOPRA Annual Symposium in Lisbon on the 23rd of October.

SMEs in a Changing World: The Impact of the Revision of the Pharmaceutical Legislation on Europe’s innovative SMEs
2023-10-11 13:30 - 15:00
In April 2023, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem.

As emerging and small companies have become innovation drivers, responsible for over two-thirds of the R&D pipeline that will become the medicines of tomorrow, changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups, emerging and small companies looking to first enter the market but also on mid-size companies looking for growth opportunities in Europe.

This event will be an opportunity to highlight the role of small and mid-size companies in developing medicines for patients, assess the foreseeable impacts of the revision on those companies, and hear directly from them what they need from the revision to continue their journey in Europe.

International Forum on Industrial Biotechnology and Bioeconomy (IFIB)
2023-09-29 10:00 - 2023-09-30 19:00
NETWORKING AND PARTNERSHIPS IN BIOECONOMY AREA

IFIB – International Forum on Industrial Biotechnology and Bioeconomy aims at strengthening the bioeconomy network in the Euro-Mediterranean area and to promote partnerships. The focus of the Forum is biotechnology, as provider of new resources for industries.

It is organized into round-tables and sessions devoted to specific sub-sectors of industrial biotechnology: bio-based industries, agro-food, energy, environment policies on industrial biotech and bioeconomy, involving international speakers coming from key sector’s players.

Edition 2023 > 29/30 September Bari

More information

BIOSPAIN 2023
2023-09-26 10:00 - 2023-09-28 19:00
BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings and companies participating. 34% of our delegates came from outside of Spain.

This year, BIOSPAIN goes back to Barcelona, the main biotech cluster in Spain and one of the most dynamic cities in the world.

The event will take place in Pavilion 1 – Fira de Barcelona – Montjuïc. It stands in a superb location in the city center, easily accessible from the airport and well-connected to the public transport network. It is located in Montjuïc Park, an area of cultural and historical interest thanks to its museums and theatres and it also features some of the main tourist attractions in Barcelona.

More information

The economic power of biotechnology for Europe
2023-09-25 12:00 - 13:15
The world is at a key point of industrial and societal transition, driven by advancing technology and the need for competitive, resilient and sustainable economies.

Biotechnology is at the heart of this transition across all sectors and it is playing a significant role in shaping Europe’s future.

European Biotech Week kick starts with a look at how biotechnology performs in the European Union’s economy.

Professor Dennis Ostwald, founder and CEO of the WifOR Institute presents the 2023 edition of EuropaBio’s ‘Measuring the economic footprint of the biotechnology industry in Europe’. Professor Ostwald showcases how biotechnology contributes across healthcare and industrial sectors in the light of Europe’s response to Covid, global supply chains stressed further by the Russian invasion of Ukraine, and at a time when Europe also has ambitious climate change goals.

Speakers:

Professor Dr. Dennis A. Ostwald. Through his studies, Prof. Ostwald aims to make the importance of health innovations visible and enable evidence-based decision making for a healthy society. He conducts research on topics such as health economics, the value of impacts, and international social policy. Prof. Ostwald studied Industrial Engineering and Management at the Technical University of Darmstadt, Germany and received his PhD from the Chair of Finance and Economic Policy, Prof. Dr. Dr. h.c. Bert Rürup, on the topic “Growth and employment effects of the healthcare industry”. As Professor of Economic Research and International Management at the Steinbeis School of International Business and Entrepreneurship (SIBE), he wants to develop young talents into responsible managers who understand the interplay between social, environmental and economic sustainability.

Join EuropaBio to understand how biotechnology is increasing its role with Europe’s economy and discuss with Members what this means for sectors, countries and citizens.

Register here

Life Sciences Baltics as a contributor to Lithuania’s innovation ecosystem
2023-09-20 08:00 - 2023-09-21 17:00
Life sciences in Lithuania have been a priority for the government for over a decade. Accelerating faster than almost anywhere else in Europe, the sector aims to contribute 5% to Lithuania’s GDP by 2030. The close cooperation between actors of the ecosystem is one of the reason for success.

Creative collaboration takes place in Lithuania’s innovation ecosystem in a variety of ways, including events, cross-promotion, and sharing of resources. The leading life sciences Baltics event in the region – Life Sciences Baltics – is one of the best examples of these collaborations.

Since its initiation in 2012, the forum has aimed to create as many opportunities as it is possible for deeper cooperation between the growing life sciences ecosystems in the Baltics and international partners.

Held every two years, the forum has grown from a 300-person assembly to a community of up to 800 key participants from around 40 countries: corporate CEOs, startup founders, tech scouts, investors, researchers. It is the largest life sciences event in the Eastern and Central Europe.

The event will take place in the Lithuania’s capital city of Vilnius on September 20-21. The pre-registration is already open for participants and exhibitors.

Whether there is a need to kick off the project, generate leads, or engage in valuable partnerships, Life Sciences Baltics offers a diverse range of interactions for its participants: international conference, exhibition, networking spaces, pitch challenge for startups.

It also hosts business delegations and offers an opportunity for side visits to Lithuania’s organizations and institutions.

The program of the international conference is divided into sessions with the most trending topics worldwide that are also breakthrough areas in the Baltic countries: gene editing, CRISPR diagnostics, AI and digital health innovations, nanomedicine, microbiome, reinvention of clinical trials, digital biomarkers and many more.

Many big names have attended Life Sciences Baltics, among them Thermo Fisher Baltics, Johnson&Johnson, Clarivate, Novartis, Abbvie, AstraZeneca, and others. Nobel prize winners Richard Henderson, Brian Kobilka, Dan Shechtman, CRISPR pioneer Prof. Dr Virginijus Šikšnys were among top conference speakers.

The event will keep tabs on the fastest growing startups in the region, but only 10 hand-picked startups will have an opportunity to showcase who they are in front of a panel of investors.

The event is organized by Innovation Agency Lithuania, an official public agency responsible for the Lithuanian innovation ecosystem and is supported by Lithuania’s local ecosystem actors – Lithuanian biotechnology association, universities, hospitals, business angels and Lithuania’s life sciences enthusiasts.

The Baltics, and Lithuania in particular, – the next big thing in life sciences

Life Sciences Baltics make it possible to assess the attractiveness of the Baltic countries in close-up – Estonia, Latvia and Lithuania show their distinct, but strong potential in the sector.

Three Baltic countries are particularly seeing a growth in life sciences startups. While average funding per startup is decreasing globally, it’s increasing in the region. Lithuania attracts growing VC interest into global solutions produced by local entrepreneurs and scientists.

Focused on nurturing the next generation of talents, the local life sciences enterprises in the Baltics excel at creativity and entrepreneurship. In 2021 alone, Lithuania’s life sciences sector grew by almost 87% and generated revenues of 2 billion euros.

90% of the output of Lithuania’s life sciences are exported to more than 100 countries worldwide. Lithuanian-made medical and pharmaceutical equipment and other products are trusted by customers in the USA, Germany, France, and elsewhere.

One of the most prominent players in Lithuania is Thermo Fisher Scientific Baltics, which has stimulated the development of Lithuania’s industry during the last decade. This company, along with other international players in the market, work with local actors for various R&D projects and supply chain.

For more details

Industrial Biotechnologies Day
2023-07-04 10:00 - 17:00
CEFIC Specialty Chemicals sector groups EFCG, Biochem Europe and EFG, together with SICOS, the French industry association for Fine Chemicals and Biotech, will jointly hold their first in-person Industrial Biotechnologies Day on July 4th, 2023 in Brussels.

Specialists from the industry, EU policy makers, and civil society will come together across four panels to dive into topics such as:

European policies shaping the biotech landscape – what is needed to unleash its full potential?

European regulatory frameworks – an obstacle to innovation?

Feedstocks and industrial capacities – what is the role of energy costs?

New technologies and future breakthroughs – what to expect and what’s at stake?

Confirmed Speakers:

Hans Ingels, European Commission – Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs

Ludo Diels, Flemish Institute for Technological Research (VITO)

Vincent Touraille, Sicos

Karel De Winter, Bio Base Europe Pilot Plant

Marcello Buson, Olon SpA

Frédéric Van Gansberghe, Futerro

Claire Skentelberry, Europabio

Christian Le Roux, Group M21

Harald Ruissenaars, Corbion

Eric Bierny, Galactic

Nicolas Martin, Metex

Thomas Canova, Solvay

Julien Honoré, Roquette

Juliette Martin, Seqens

Gwenaël Servant, Abolis

More details

DUTCH BIOTECH EVENT 2023
2023-06-30 12:45 | Inn Style, Herenweg 55, Maarssen, 3602 AN, Netherlands
Join us to celebrate the power of biotech at the Dutch Biotech Event 2023!

About HollandBIO’s Dutch Biotech Event

The program features inspiring talks by keynote speakers on biotech and entrepreneurship, followed by workshops and break-out sessions that contribute to your personal development and that of your company. In addition, there will be plenty of opportunities for networking during the break, drinks and vegetarian BBQ.

Who can join Dutch Biotech Event?

The Dutch Biotech Event welcomes HollandBIO members (registration free of charge) and employees of other biotech R&D companies (registration fee €295,- p.p.), with a maximum of 2 delegates per organization.

We invite non-member startups to consider a HollandBIO membership (€562,-/year), which besides access to the network & events, offers many more advantages.

More information

NAC Spanish Presidency Summer Reception
2023-06-27 18:00 - 20:00
EuropaBio, and AseBio, the Spanish Association of Biotechnology Companies, with the support of Merck, will host a summer reception to mark the beginning of the Spanish Council Presidency of the European Union and present the outcomes of their National Association Council Presidency Summit.

The event will take place on June 27th in Brussels at Comet Meetings – Louise, from 18-20h. If you wish for more details, please get in touch with José Peres at j.peres@europabio.org

Reflection seminar and closing party around the EU presidency
2023-06-27 14:00 - 16:00 | IVA Conference Center, Grev Turegatan 15, Stockholm, Sweden
On June 27, a Life Science conference is arranged for EU parliamentarians during Sweden’s EU presidency.

Directly after the official conference, The Royal Academy of Engineering Sciences (IVA) and SwedenBIO invites the public to a seminar with the spotlight on how the suggested EU legislations may affect the life science industry. With examples from the Swedish life science arena, we show the importance of intellectual property and data protection in the journey from academic research to products and therapies for patients.

Afterward, a networking reception is organized by the united life science industry organisations. With drinks, snacks, and key speakers, we ensure that the end of the presidency marks the start of an even stronger united life science industry in Sweden and beyond.

More details

EuropaBio National Associations Council Summit 2023 (Spanish Presidency): A global Europe - the role of transformative legislation
2023-06-22 14:00 - 16:00
Spain will hold the Presidency of the Council of the European Union for the fifth time in the second half of 2023, between July 1 and December 31. In a pivotal time for the Biotechnology industry, Spain will lead the dialogue on the European Commission’s proposal on new genomic techniques (NGT) and the revision of the Pharmaceutical Strategy for Europe – critical policies for European patients, Europe’s food security and the green transition.

EuropaBio – the European Association for Bioindustries and AseBio, the Spanish Association of Biotechnology Companies, are proud hosts of EuropaBio’s National Associations Council (NAC) annual Presidency Summit. Invited speakers from industry, policymakers, and national biotechnology associations will explore the latest policy developments and offer their insights into the upcoming work and ambitions of the Spanish Council Presidency.

The Summit will be public and held online on June 22. The event will be followed by a Summer reception on June 27 in Brussels to present our participants’ key messaging and recommendations.

If you wish to attend our session or have any questions, insights or suggestions, please do not hesitate to reach José Peres at j.peres@europabio.org.

Agenda

Opening remarks

Tineke Van hooland, Deputy Secretary General at bio.be/essenscia, Chair of the National Associations Council (NAC) at EuropaBio

Panel I: Innovation for European Patients: the European pharmaceutical legislation

MEP Dolors Montserrat (EPP)

Ana Polanco, AseBio Chair of the Board, Head of European Government and Public Affairs, and Market Access and Pricing at Merck

Dr Jessica Martinsson, Director General at SwedenBio

Maria Pascual, Chief Regulatory Officer at Minoryx Therapeutics

Moderation: Vlad Olteanu, Healthcare Public Affairs Director at EuropaBio

Panel II: Resilience, sustainability and competitiveness for Europe’s food chain: new genomic techniques

Ilaria Ciabatti, Team Leader Biotechnology Unit, European Commission DG Santé

Ion Arocena Vélez, Director General at AseBio – the Spanish Association of Biotechnology Companies

Elke Duwenig, Senior Expert Global Regulatory / Public & Government Affairs Biotechnology, Nutrition & Health at BASF

Oana Dima, Executive Manager of the EU-SAGE network, Science Policy Manager at VIB-Ghent University Center for Plant Systems Biology

Tomasz Zimny, Assistant Professor at the Institute of Law Studies, Polish Academy of Sciences, Warszawa, Poland

Ana Judith Martín de la Fuente, Head of Area/Secretary of the Interministerial Council of GMOs at the Spanish Ministry of Agriculture, Food and Fisheries

Moderation: Anne-Gaelle Collot, Industrial Biotechnology Director at EuropaBio

Closing remarks

Claire Skentelbery, Director General at EuropaBio

Register here

GREEK BIOPHARMA INNOVATION: Your changing world with the new EU Pharma Legislation
2023-06-16 08:30 - 10:00 | Megaron Athens International Conference Centre, Athens, Greece
Chairperson: Claire Skentelbery, Director General EuropaBio

Participants:

Kostas Papagiannis Country President & Managing Director Novartis Greece

Hardy Rideout Anacalypsis Therapeutics

George Drakakis CEO PurposefulEU pharma legislation is going to change your business. What you make, where and how you sell it, and whether your business model is even viable.The European Commission published new legislative proposals in April that will redefine the business model of biotechnology in Europe. In trying to bring medicines to more patients, the legislation proposals reduce data protection, limit exclusivity for orphan medicines and brings heavy pressure to launch in all 27 Member States within two years of EMA approval.Changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups, those seeking scale up investment, clinical trials and companies going to market, often for the first time.This session/panel, chaired by EuropaBio, presents the key impacts points for biotechnology innovation within Greece, with contributions from small and large companies and policy makers – bring your voice to the discussion for the future of your own science.

More information

3rd Hellenic Biocluster Forum
2023-06-15 08:00 - 2023-06-17 18:00 | Megaron Athens International Conference Centre, Athens, Greece
The Hellenic BioCluster is organizing its 3rd Forum on the subject of “Supporting disruptive innovation to maximize the economic and social impact of the bio-industry sector”, scheduled to be held between 15 – 17 June 2023 at Megaron Athens International Conference Centre, Athens, Greece.

The 3rd HBio Forum features a 3-day, cutting-edge programme with inspiring speakers from across the globe, all experts in disruptive innovation, with the aim to connect the global biotech innovation community under the sunny Athens skies. During the Forum B2B meeting opportunities will be provided between attendees and sponsors/exhibitors.

The 3rd HBio Forum will also include targeted panels of industry experts, mentors and life sciences professionals to discuss hot topics related to investment such as raising capital and achieving success, followed by a Pitching Competition.

More Details

EuropaBio: BIO 2023
2023-06-05 17:30 - 18:30 | Boston Convention & Exhibition Center, Boston, Massachusetts, United States
Round table –Biomanufacturing for health: advancing healthcare and global preparedness

EuropaBio is pleased to host a round table discussion at the upcoming BIO International Convention in Boston and invites all delegates to join us to discuss on biomanufacturing for health: advancing healthcare and global prepareness.

Biomanufacturing within healthcare represents an advance in therapeutic capabilities, as ground-breaking research translates into increased diseases that can be targeted, either for the first time or with greater efficacy, with increasingly complex interventions becoming possible. It also brings resilience and increased environmental sustainability to strained supply chains as the world strives to modernise production systems.

The transition has significant implications for global healthcare, competitiveness, sustainability and resilience, with capacity building important in all regions.

This is not just reflected in advancing healthcare for citizens but also for the world’s ability to respond to healthcare crises. Covid demonstrated that biomanufacturing capacity globally was called into action from multiple applications and countries for the complex manufacturing process behind vaccines.

This biomanufacturing capacity does not exist within a vacuum, ready to be called to action when needed. It requires drug developers large and small, public and private, specialised manufacturers, plus skills base, supply chain and logistics frameworks resulting from significant investment over many years.

Importantly, a sustainable biomanufacturing framework is financed and delivered primarily through industry, meaning that is must be integral to company strategy. This is not a guarantee, as the global healthcare industry reacts to legislative changes and government strategies, with major investment decisions having long term implications for the capacity and skills base within countries and regions.

What does the world need to get right to ensure that biomanufacturing capacity grows, to serve patients with advancing therapies and be there for coordinated emergency responses?

Participants within the round table reflect global biomanufacturing stakeholders and will discuss:

National policies, incentives and strategy

Regulatory and standards and alignment

International cooperation and development

The output from this roundtable will be a call to global action for biomanufacturing published through EuropaBio and BIO, with all delegates invited to contribute through the round table and follow up.

Agenda

10:30Welcome and introductionEuropaBio and BIO10:40Setting the scene for global biomanufacturing and the planned outcome from the round tableClaire10:45(draft) Discussion points for participants: – What does your country need to achieve for resilience through national or accessible biomanufacturing capacity?– How are regulatory frameworks adapting to an increasingly biological pipeline of medicines?– What does international cooperation need to achieve to ensure that manufacturing is actually possible during pandemic responses?– Name a priority for you to reach biomanufacturing goals in the coming years.All participants: Lead interventions on specific topics11:30Closing remarksEuropaBio and BIO

More information here

KNOWLEDGE FOR GROWTH 2023
2023-06-01 10:00 - 19:00 | Flanders Meeting & Convention Center Antwerp, Koningin Astridplein 26, Antwerp, 2018, Belgium
Knowledge for Growth is Europe’s finest life sciences conference.For the first time the event will take place in Antwerp.

The conference features an exciting programme providing vital insight into the global life sciences’ landscape, one-to-one partnering, a trade fair and more!

LEARN. CONNECT. DISCOVER.

The cream of the Belgian life sciences community attends flanders.bio’s annual Knowledge for Growth business conference, attracting decision makers from biotech, pharma and medtech, agricultural and chemical industry as well as investors, universities, top-notch research institutes, policymakers and competence providers.

More information

ESAB-SusChem Webinar Sustainable Chemistry
2023-05-26 10:00 - 12:00
The European Society of Applied Biocatalysis (ESAB) and the European Technology Platform for Sustainable Chemistry (SUSCHEM) will held a Webinar on Sustainable Chemistry, chaired by Pablo Domínguez de María (Sustainable Momentum SL, ESAB Working Group Sustainable Chemistry, SusChem Management Team) and Andrés R Alcántara (Complutense Univ of Madrid, ESAB Working Group Sustainable Chemistry, SusChem Board).

PROGRAMME

10:00 -10:30. MSc Irantzu Garmendia Aguirre, Project Officer Safe and Sustainable by Design (SSbD), European Commission, Directorate General Joint Research Centre, Ispra, Italy.Title: EC Recommendation for Safe and Sustainable by Design (SSbD) Chemicals Materials: scientific assessment framework policy context.

10:30- 11:00. Prof. Dr. Dunming Zhu, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.Title: Biocatalytic Synthesis of High Value Chemicals from Simple and/or Renewable Starting Materials.

11:00-11:30. Dr. Fabrice Gallou, Novartis Distinguished Scientist-Director Science & Technology Chemical Development, Novartis, Basel, Switzerland.Title: Sustainability as a driver for innovation.

11:30- 12:00. Prof. Dr. Dean Brady, Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa.Title: Biocatalysis in the synthesis of amines and amides.

More information here
